Hypoxia Analysis in Head and/or Neck Cancer

NCT ID: NCT02414048

Last Updated: 2016-06-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2022-10-31

Brief Summary

The primary objective is the prospective determination of disease-specific and overall survival in head and neck cancer patients who have undergone surgery, correlated to non-invasive methods of measuring tumour hypoxia.

The secondary objective is to define tumour hypoxia using non-invasive methodology.

Detailed Description

The incidence of head and neck squamous cell cancer (HNSCC) is around 600 000 cases per year worldwide. The main sites for HNSCC are the larynx, the pharynx and the oral cavity. Head and neck cancers, however, also include salivary gland tumours, as well as nasopharyngeal cancer and paranasal and nasal sinus cancer but these are rare. The major risk factors are smoking, alcohol abuse and Human Papillomavirus (HPV) infection. In spite of radical surgical treatment and aggressive neo-adjuvant and adjuvant therapies, the prognosis of head and neck cancer is very poor due to the fact that the tumours are often hypoxic.

Tumour hypoxia is heterogenous and results from an imbalance between oxygen supply and oxygen consumption. Acute hypoxia is caused by abnormal structure and function of the microvasculature supplying the tumour. Chronic hypoxia is caused by the increased distance through which the oxygen has to diffuse to get from the blood vessels to the tumour cells and by the reduced oxygen caused by the anaemia which can be treatment or disease-related. These hypoxic regions have been shown to affect the metabolism of the cells, making them more aggressive with increased risk of metastasis and a worse prognosis. Also, because radiotherapy relies on oxygen to cause maximal cytotoxicity, a lack of oxygen to the cells or even a lack of oxygen consumption by the cells would cause a decrease in the effectiveness of the radiotherapy and the cytotoxicity. Hypoxic cells have an acidic environment which affects drug delivery and drug activity, so chemotherapy is compromised.

In order to predict outcome and identify patients with a worse prognosis or patients that would benefit from appropriate treatments, in vivo measurement of tumour hypoxia is required. Numerous methods have been explored but there is no accepted gold standard. Imaging and biomarker analysis have been shown to have potential but the data are insufficient. In this project the investigators would prospectively use existing imaging techniques and analysis of various bodily fluids to predict outcome. This is a collaboration between 5 different departments so that as much information as possible can be analysed and used to come to a possible solution.

Conditions

Head and Neck Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Pimonidazole

All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour

Group Type: OTHER

Pimonidazole

Intervention Type: DRUG

Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour

Interventions

Pimonidazole

Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour

Intervention Type: DRUG

Other Intervention Names

Oral Hypoxyprobe

Eligibility Criteria

Inclusion Criteria

• Malignancy in head and/or neck region only
• Interdisciplinary Head and neck tumour board (USZ) confirmed inclusion in the project
• For patients with reproductive potential (e.g. female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as beig of child bearing potential), a willingness to use adequate contraceptive measures to prevent pregnancy during the project.

Exclusion Criteria

• Pregnant or breastfeeding
• Suffers from claustrophobia
• Known allergy to Pimonidazole
• Participation in a study with an investigational drug within the 30 days preceding and during this project
• Tumour size smaller than 1cm
• Has symptomatic Chronic Obstructive Pulmonary Disease (COPD)
• Patient refuses or is unable to give a written informed consent
• Previous treatment for head and/or neck cancer
• Inability to follow the procedures of the project e.g. due to language problems, psychological disorders, dementia, etc. of the participant.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Marius Gustav Bredell

OTHER

Sponsor Role: lead

Responsible Party

Marius Gustav Bredell

Dr

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Marius Bredell

Role: PRINCIPAL_INVESTIGATOR

Department of Cranio-, Maxillofacial and Oral Surgery, University Hospital Zurich

Locations

Department of Cranio-, Maxillofacial and Oral Surgery

Zurich, , Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Christine Hager

Role: CONTACT

christine.hager@usz.ch

Facility Contacts

Christine Hager

Role: primary

christine.hager@usz.ch

Other Identifiers

KEK-Nr.2014-0393

Identifier Type: -

Identifier Source: org_study_id